Novartis upholds MS drug patent at Fed Circ

Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya (fingolimod hydrochloride) was valid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Biotech wins $16.5 million in drug royalties dispute

18 October 2022 Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

Big Pharma

Fed Circuit reverses Novartis’ drug patent win

23 June 2022 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

Americas

Boston Pharma reaches deals with GSK and Novartis

4 October 2018 Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.